DelveInsight’s “Hepatic Cirrhosis Market Insights, Epidemiology, and Market Forecast-2032” analysis provides comprehensive understanding of Hepatic Cirrhosis, encompassing historical and projected epidemiology alongside market trajectories across the United States, EU5 nations (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Download analysis @https://www.delveinsight.com/report-store/hepatic-cirrhosis-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Recent Advancements in the Hepatic Cirrhosis Marketplace:
- In June, Grifols Therapeutics LLC initiated a Phase 3 clinical investigation for Albutein 20% Injectable Solution. This open-label, randomized, controlled, parallel-group investigation is conducted across multiple medical centers. The primary objective is to evaluate efficacy of combining Albutein 20% with standard medical treatment (SMT) versus SMT alone in patients with decompensated cirrhosis and ascites.
- Also in June, AstraZeneca initiated a Phase 2 clinical investigation examining zibotentan (dose B) in combination with dapagliflozin, as well as a placebo group (matching zibotentan capsules and dapagliflozin tablets). This investigation, comprising Phase IIa and IIb, represents a randomized, double-blind, placebo-controlled trial conducted in parallel groups at multiple centers. Its primary objective is to evaluate effectiveness, safety, and tolerability of the zibotentan-dapagliflozin combination and dapagliflozin monotherapy compared to placebo, focusing on participants with cirrhosis and signs of portal hypertension.
Essential Highlights from the Hepatic Cirrhosis Market Analysis:
- In 2017, cirrhosis caused more than 1.32 million deaths globally, compared with less than 899,000 deaths in 1990. Deaths due to cirrhosis constituted 2.4% of total deaths globally in 2017 compared with 1.9% in 1990. Despite an increase in the number of deaths, the age-standardized death rate decreased from 21.0 per 100,000 population in 1990 to 16.5 per 100,000 population in 2017.
- Recently in a large secondary care hospital, Hsiang et al. demonstrated that the common primary aetiologies for liver cirrhosis were chronic hepatitis B cirrhosis (37.3%), alcoholic liver disease cirrhosis (24.1%), chronic hepatitis C cirrhosis (22.3%), and non-alcoholic fatty liver disease cirrhosis (16.4%).
- According to Vaz et al., the age-standardized incidence was calculated at 23.2 per 100,000 person-years, 30.5 for men, and 16.4 for women. When stratified by age, the highest incidence rates were registered at age 60-69 years. Men had higher incidence rates for most age groups when compared to women.
- The Hepatic Cirrhosis marketplace is expected to strengthen as disease awareness increases and more effective interventions are being developed.
- Leading Hepatic Cirrhosis Companies operating in the marketplace include NGM Biopharmaceuticals Inc, Conatus Pharmaceuticals Inc, Grifols Therapeutics LLC, Norgine, Mallinckrodt, Intercept Pharmaceuticals, and others.
Key Benefits of the Hepatic Cirrhosis Market Analysis:
- Hepatic Cirrhosis market analysis covers comprehensive overview and extensive insight of Hepatic Cirrhosis Epidemiology and marketplace in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
- The Hepatic Cirrhosis market analysis provides insights on current and emerging therapeutics.
- Hepatic Cirrhosis market analysis provides global historical and forecasted market covering pharmaceutical outreach in 7MM.
- The Hepatic Cirrhosis market analysis offers advantages that will help in developing business strategies by understanding trends shaping and driving the marketplace.
Have questions? Click here to discover more about the Hepatic Cirrhosis Market Landscape @ https://www.delveinsight.com/report-store/hepatic-cirrhosis-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Understanding Hepatic Cirrhosis
Hepatic cirrhosis represents a late-stage liver disease characterized by replacement of healthy liver tissue with scar tissue, resulting in permanent liver damage. This condition arises from various liver diseases and conditions that cause cell injury, inflammation, and eventual scarring due to repair processes. As scar tissue accumulates, it obstructs blood flow through the liver, impeding its capacity to process nutrients, hormones, pharmaceuticals, and natural toxins. Additionally, it diminishes liver production of essential proteins and other substances. Ultimately, cirrhosis impairs liver function, and late-stage cirrhosis can be life-threatening.
In developed countries, primary causes of cirrhosis include hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). In developing regions, hepatitis B virus (HBV) and HCV are more prevalent causes. Other factors contributing to cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver damage, and chronic right-sided heart failure.
Cirrhosis is classified based on symptom presentation: decompensated cirrhosis is marked by noticeable symptoms including jaundice, ascites (fluid accumulation in the abdomen), and hepatic encephalopathy (confusion and coma), while compensated cirrhosis does not produce these symptoms.
Complications of cirrhosis arise due to impaired liver function and disrupted blood flow. Major complications include esophageal varices and variceal hemorrhage, ascites, infections in the abdominal cavity, hepatic encephalopathy, hepatorenal syndrome, and various lung and heart complications.
Discover more details about hepatic cirrhosis marketplace @ https://www.delveinsight.com/report-store/hepatic-cirrhosis-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Hepatic Cirrhosis Market Analysis
The Hepatic Cirrhosis marketplace is expected to undergo substantial transformation in forthcoming years due to anticipated introduction of new therapeutics from organizations including Galectin Therapeutics, Pharmicell, Madrigal Pharmaceuticals, CymaBay Therapeutics, and Galmed Pharmaceuticals, among others, throughout the forecast period from 2019 to 2032.
Hepatic Cirrhosis Treatment Market
The hepatic cirrhosis treatment marketplace is experiencing robust expansion, driven by rising incidence of liver diseases and growing demand for effective therapies. Hepatic cirrhosis, marked by progressive liver scarring that can result in liver failure without intervention, represents a serious condition. Market expansion is fueled by advancements in treatment alternatives, including liver transplantation, pharmacological therapies, and minimally invasive procedures. DelveInsight’s Hepatic Cirrhosis market analysis offers a comprehensive evaluation of the condition, detailing aspects including disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment strategies.
To discover how the hepatic cirrhosis marketplace is expanding in the upcoming years, visit: https://www.delveinsight.com/report-store/hepatic-cirrhosis-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Hepatic Cirrhosis Pipeline Therapeutics and Principal Companies
- Belapectin: Galectin Therapeutics
- Cellgram_LC: Pharmicell
- MGL-3196: Madrigal Pharmceuticals
- Seladelpar: Cymabay Therapeutics
- Aramchol: Galmed Pharmaceuticals
Table of Contents
- Report Introduction
- Executive Summary
- SWOT analysis
- Hepatic Cirrhosis Patient Share (%) Overview at a Glance
- Hepatic Cirrhosis Market Overview at a Glance
- Hepatic Cirrhosis Disease Background and Overview
- Hepatic Cirrhosis Epidemiology and Patient Population
- Country-Specific Patient Population of Hepatic Cirrhosis
- Hepatic Cirrhosis Current Treatment and Medical Practices
- Unmet Needs
- Hepatic Cirrhosis Emerging Therapies
- Hepatic Cirrhosis Market Outlook
- Country-Wise Hepatic Cirrhosis Market Analysis (2019-2032)
- Market Access and Reimbursement of Therapies
- Market drivers
- Market barriers
- Appendix
- Hepatic Cirrhosis Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Download our sample analysis @ https://www.delveinsight.com/report-store/hepatic-cirrhosis-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
